新型抗青光眼药物——固定联合制剂

发布时间：2019-06-19 10:30

【摘要】：近年新型抗青光眼药物——固定联合制剂陆续在我国上市。固定联合制剂是由两种或两种以上不同降眼压机制的青光眼药物联合组成,降压效果强于单制剂或不劣于它们协同使用。固定联合制剂仍然存在与单制剂类似的副作用,但少于单制剂。固定联合制剂为临床上使用两种以上药物降眼压患者提供更有力的降压效果,提高治疗方案的便利性,减少多瓶用药防腐剂对眼表的损害,改善病人的依从性和药物治疗的持久性。
[Abstract]:In recent years, new antiglaucoma drugs-fixed combination preparations have been listed in China. Fixed combination is composed of two or more glaucoma drugs with different mechanisms of reducing intraocular pressure, and the antihypertensive effect is stronger than or no worse than that of single preparation or their combination. Fixed combination preparations still have similar side effects to single preparations, but less than single preparations. The combination of fixed preparation provides more powerful antihypertensive effect for patients with more than two kinds of drugs in clinical use, improves the convenience of treatment, reduces the damage to eye surface caused by multiple bottles of preservatives, and improves the compliance of patients and the persistence of drug therapy.
【作者单位】：第三军医大学野战外科研究所大坪医院眼科;
【分类号】：R988.1

【相似文献】